A multicenter, randomized, open-label clinical trial to evaluate safety and tolerability of a year-round initiation of specific immunotherapy with an aluminum hydroxide adsorbed allergoid preparation of 6-grasses in patients with moderate to severe seasonal rhinitis or rhinoconjunctivitis with or without controlled asthma.

Trial Profile

A multicenter, randomized, open-label clinical trial to evaluate safety and tolerability of a year-round initiation of specific immunotherapy with an aluminum hydroxide adsorbed allergoid preparation of 6-grasses in patients with moderate to severe seasonal rhinitis or rhinoconjunctivitis with or without controlled asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Rhinoconjunctivitis; Seasonal allergic rhinitis
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms SuBITo
  • Sponsors Allergopharma
  • Most Recent Events

    • 28 Oct 2017 Status changed from recruiting to completed.
    • 17 Jun 2016 Planned number of patients changed from 160 to 240.
    • 07 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top